Abstract

BackgroundPerihepatitis is rare but consistently occurring extragenital manifestation of untreated Chlamydia trachomatis infection. Despite of possible liver involvement in generalized C. trachomatis infection, the ability of the pathogen to propagate in the hepatic cells and its impact on liver functions is not thoroughly investigated. The effect of mevastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, on C. trachomatis growth in human hepatoma cell line HepG2 has been studied. Bacterial growth was assessed by immunostaining with FITC-labeled monoclonal antibody against chlamydial lipopolysaccharide and by RT-PCR for two chlamydial genetic markers (16S rRNA and euo).ResultsChlamydial inclusion bodies were seen in approximately 50% of hepatocytes at 48 hours in the post infection period. Lysates obtained from infected hepatocytes were positive in the infective progeny test at 48 and especially in 72 hours after infection initiation. It has been shown that chlamydial infection in hepatocytes also leads to the decline of LDL-receptor mRNA which reflects infection multiplicity rate. Additions of mevastatin (1, 20 and 40 μM) 1 hour before inoculation restored and upregulated LDL-receptor mRNA level in a dose-dependent manner. Mevastatin treatment had no effect on internalization of chlamydial particles. However it reduced drastically the number of chlamydial 16S rRNA and euo transcripts as well as overall infection rate in HepG-2 cells. Complete eradication of infection has been seen by immunofluorescent staining at 40 μM mevastatin concentration, when expression level of chlamydial 16S rRNA and euo was undetectable. Lower concentration of mevastatin (20 μM) promoted euo expression level and the appearance of atypically small chlamydial inclusions, while there was a noticeable reduction in the number of infected cells and 16S rRNA transcripts.ConclusionsC. trachomatis can efficiently propagate in hepatocytes affecting transcription rate of some liver-specific genes. Ongoing cholesterol synthesis is essential for chlamydial growth in hepatocytes. Inhibitors of cholesterol biosynthesis can supplement conventional strategy in the management of C. trachomatis infection.

Highlights

  • Perihepatitis is rare but consistently occurring extragenital manifestation of untreated Chlamydia trachomatis infection

  • In the present paper we have investigated the infectability of C. trachomatis toward immortalized human hepatoma cells (HepG2 cell line) and some metabolic consequences of chlamydia propagation in the hepatic cell line

  • C. trachomatis growth in HepG2 cells Immunofluorescent images of HepG2 infected cells reveal that C. trachomatis can efficiently grow in immortalized hepatocytes cells line

Read more

Summary

Introduction

Perihepatitis is rare but consistently occurring extragenital manifestation of untreated Chlamydia trachomatis infection. Despite of possible liver involvement in generalized C. trachomatis infection, the ability of the pathogen to propagate in the hepatic cells and its impact on liver functions is not thoroughly investigated. The effect of mevastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, on C. trachomatis growth in human hepatoma cell line HepG2 has been studied. Chlamydia trachomatis is a prevalent bacterial pathogen causing most of the cases of urogenital infections and preventable blindness in the world. Among most frequent extragenital manifestations of C. trachomatis are sexually acquired reactive arthritis (SARA), conjunctivitis and perihepatitis [1]. It is believed that immunological and hormonal phenotype as well as some genotype characteristics, expression of human leucocyte antigen B27, predetermine the severity of extragenital manifestations caused by C. trachomatis [3]. Delayed cell-mediated immunological response is known to play an important role in the systemic generalization of chlamydial disease [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call